Evidence map›Paper›PMID 40938707›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Subtype-specific structural features of the hearing loss-associated human P2X2 receptor.

Franka G Westermann, Adam C Oken, Philip K E Granith, Parthiban Marimuthu, Christa E Müller, Steven E Mansoor

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Franka G WestermannPharmaCenter Bonn and Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, Bonn 53121, Germany.ORCID 0009-0008-2562-561X
Adam C OkenDepartment of Chemical Physiology & Biochemistry, Oregon Health & Science University, Portland, OR 97239.ORCID 0000-0002-8661-9888
Philip K E GranithPharmaceutical Science Laboratory (Pharmacy) and Structural Bioinformatics Laboratory (Biochemistry), Faculty of Science and Engineering (FNT), Åbo Akademi University, Turku FI-20520, Finland.ORCID 0009-0004-9344-8847
Parthiban MarimuthuPharmaceutical Science Laboratory (Pharmacy) and Structural Bioinformatics Laboratory (Biochemistry), Faculty of Science and Engineering (FNT), Åbo Akademi University, Turku FI-20520, Finland.ORCID 0000-0003-4960-2160
Christa E MüllerPharmaCenter Bonn and Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, Bonn 53121, Germany.ORCID 0000-0002-0013-6624
Steven E MansoorDepartment of Chemical Physiology & Biochemistry, Oregon Health & Science University, Portland, OR 97239.ORCID 0000-0001-9606-8955

Funding

Pacific Northwest Center for Cryo-EM - Screening supplementU24GM129547 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI EVANS, JAMES E, GOUAUX, JAMES E · 2018 to 2023
$54.8M
Elucidation of P2X7 Receptor Signaling and Development of Novel Small Molecule and Aptamer Ligand TherapiesDP2GM149551 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI MANSOOR, STEVEN ELIAS · 2022 to 2025
$2.3M
Structure/Function Studies on the Mechanisms of Purinergic Receptor Activation and AntagonismR00HL138129 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI MANSOOR, STEVEN ELIAS · 2020 to 2022
$746k
American Heart Association (AHA) 24PRE1195450Deutsche Forschungsgemeinschaft (DFG) 494832089Deutsche Forschungsgemeinschaft (DFG) DFG SFB 1328European Commission (EC) CA21130HHS | NIH | National Institute of General Medical Sciences (NIGMS) DP2GM149551HHS | NIH | NHLBI | Division of Intramural Research (DIR) R00HL138129NHLBI NIH HHS R00 HL138129NIGMS NIH HHS DP2 GM149551NIGMS NIH HHS U24 GM129547
6 · The paper itself

Abstract

The P2X2 receptor (P2X2R) is a slowly desensitizing adenosine triphosphate (ATP)-gated ion channel that is highly expressed in the cochlea. When mutated, the P2X2R exacerbates age- and noise-related hearing loss, but selective modulators of the receptor are lacking, and the molecular basis of activation and desensitization remains poorly understood. Here, we determine high-resolution cryoelectron microscopy structures of the full-length wild-type human P2X2R in an apo closed state and two distinct ATP-bound desensitized states. In the apo closed state structure, we observe features unique to the P2X2R and locate disease mutations within or near the transmembrane domain. In addition, our ATP-bound structures show how free anionic ATP forms subtype-specific interactions with the orthosteric binding site. We identify and characterize two different ATP-bound desensitized state structures, one similar to published models for other P2XR subtypes, and a second alternate conformation not previously observed. A loop adjacent to the orthosteric binding site between these two ATP-bound desensitized state structures undergoes significant conformational changes. These movements are supported by multireplicate, microsecond-scale molecular dynamics simulation studies and suggest a path by which ATP could enter or leave the orthosteric pocket. Together, our results provide structural insights into the P2X2R, facilitating structure-based drug development for this therapeutically important target.

Indexed as

Hearing LossReceptors, Purinergic P2X2Adenosine TriphosphateBinding SitesCryoelectron MicroscopyHumansModels, MolecularMutationProtein ConformationAdenosine TriphosphateP2RX2 protein, humanReceptors, Purinergic P2X2ATPcryo-EMligand-gated ion channelsmolecular dynamics (MD) simulationspurinergic P2X2 receptor

Identifiers

PMID40938707
PMCPMC12452952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.